Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biden Says Administration Working With Vaccine Manufacturers on Contingency Plans to Combat New Variant

11/29/2021 | 12:51pm EST

By Tarini Parti

President Biden said his administration was working with officials at Pfizer Inc., Moderna Inc. and Johnson & Johnson to develop contingency plans for vaccines or boosters in case they are needed to combat the Omicron variant of the coronavirus.

Mr. Biden said at this time officials don't think such additional measures will be needed.

He also said he will soon release a strategy outline for how the administration plans to deal with Covid-19 this winter, adding that the plans would focus on more vaccinations, boosters and testing rather than lockdowns.

"This variant is a cause for concern, not a cause for panic," he said.

Write to Tarini Parti at tarini.parti@wsj.com

(END) Dow Jones Newswires

11-29-21 1251ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 0.98% 164.35 Delayed Quote.-37.66%
JOHNSON & JOHNSON 1.24% 170.5 Delayed Quote.-1.57%
MODERNA, INC. 0.18% 156.15 Delayed Quote.-38.99%
PFIZER, INC. 1.74% 53.47 Delayed Quote.-10.23%
All news about MODERNA, INC.
09:38aModerna, IAVI Say Clinical Trial of Experimental HIV Vaccine Antigens is Underway
MT
09:19aMODERNA : IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Tec..
PU
09:09aWALL STREET STOCK EXCHANGE : Are we still in the Goldilocks zone?
08:57aMARKETSCREENER'S WORLD PRESS REVIEW : January 27, 2022
01/26Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study
MT
01/26Moderna Launches Mid-Stage Study of Omicron-Specific Booster Jab
MT
01/26Moderna starts trial for Omicron-specific booster shot
RE
01/26Moderna starts trial testing Omicron-specific booster shot
RE
01/26MODERNA : Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster C..
PU
01/26Moderna begins testing omicron-matched COVID shots in adults
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 769 M - -
Net income 2021 11 260 M - -
Net cash 2021 11 938 M - -
P/E ratio 2021 5,83x
Yield 2021 -
Capitalization 62 828 M 62 828 M -
EV / Sales 2021 2,86x
EV / Sales 2022 1,85x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 154,96 $
Average target price 265,41 $
Spread / Average Target 71,3%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601
CELLTRION, INC.-21.21%18 165